ArticleFrontiers in oncology2023

The great need to overcome osimertinib resistance in advanced non-small cell lung cancer: from combination strategies to fourth-generation tyrosine kinase inhibitors.

Giuseppe Bronte et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.